Related Experiment Video

Updated: Mar 31, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.9K

Thyroid dysfunction and dyslipidemia in chronic kidney disease patients

Saroj Khatiwada1, K C Rajendra2, Sharad Gautam3

  • 1Department of Pharmacy, Central Institute of Science and Technology (CIST) College, Pokhara University, Kathmandu, 44600, Nepal. khatiwadasaroj22@gmail.com.

BMC Endocrine Disorders
|October 30, 2015
PubMed

Insights

Thyroid dysfunction and abnormal lipid profiles are common in chronic kidney disease (CKD) patients. Advanced CKD stages correlate with increased risks of hypothyroidism and cardiovascular disease.

Area of Science:

  • Nephrology
  • Endocrinology
  • Cardiology

Background:

  • Chronic kidney disease (CKD) is a growing global health concern with increasing prevalence.
  • CKD progression is linked to serious complications like thyroid dysfunction, dyslipidemia, and cardiovascular diseases (CVD).

Purpose of the Study:

  • To investigate the prevalence of thyroid dysfunction and lipid profile abnormalities in patients with chronic kidney disease.
  • To explore the relationship between CKD progression and these complications.

Main Methods:

  • A cross-sectional study involving 360 CKD patients.
  • Collected demographic data and medical history (diabetes, hypertension, CVD).
  • Analyzed blood samples for renal function markers, thyroid hormones (T3, T4, TSH), and lipid profiles (total cholesterol, HDL, LDL, triglycerides).

Main Results:

  • Thyroid dysfunction observed in 38.6% of CKD patients, primarily subclinical hypothyroidism (27.2%).
  • Dyslipidemia was prevalent: hypercholesterolemia (34.4%), low HDL (34.1%), high LDL (35%), and hypertriglyceridemia (36.6%).
  • Patients with Stage 4 and 5 CKD showed a significantly higher risk of thyroid dysfunction and CVD compared to Stage 3.

Conclusions:

  • Thyroid dysfunction and various forms of dyslipidemia are highly prevalent in CKD patients.
  • Hypothyroidism and cardiovascular disease risk increase with CKD progression.
Abstract

More Related Videos

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.9K

Related Concept Videos

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
950
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
621
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
607
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
1.1K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
335
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
312